Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis

被引:77
|
作者
Nakano, Chikako [1 ]
Hamano, Takayuki [1 ,2 ]
Fujii, Naohiko [3 ]
Obi, Yoshitsugu [1 ]
Matsui, Isao [1 ]
Tomida, Kodo [4 ]
Mikami, Satoshi [5 ]
Inoue, Kazunori [1 ]
Shimomura, Akihiro [1 ]
Nagasawa, Yasuyuki [1 ]
Okada, Noriyuki [6 ]
Tsubakihara, Yoshiharu [6 ]
Rakugi, Hiromi [1 ]
Isaka, Yoshitaka [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Geriatr Med & Nephrol, Suita, Osaka, Japan
[2] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Pennsylvania, PA USA
[3] Hyogo Prefectural Nishinomiya Hosp, Dept Internal Med, Hyogo, Japan
[4] Kansai Rosai Hosp, Dept Internal Med, Hyogo, Japan
[5] Higashi Kohri Hosp, Dept Internal Med, Osaka, Japan
[6] Osaka Gen Med Ctr, Dept Hypertens & Nephrol, Osaka, Japan
关键词
Chronic kidney disease; Cardiovascular disease; Fibroblast growth factor 23; Mineral metabolism; Risk stratification; CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; SERUM ALKALINE-PHOSPHATASE; VITAMIN-D LEVELS; RENAL-FUNCTION; VASCULAR CALCIFICATION; DIETARY PHOSPHATE; ALL-CAUSE; MORTALITY; RISK;
D O I
10.1016/j.bone.2012.02.634
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Low 25-hydroxyvitamin D (25D), increased levels of fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and alkaline phosphatase (ALP) were reported to be risk factors for mortality in chronic kidney disease (CKD). However, the independent associations of these factors with cardiovascular disease (CVD), the leading cause of death among CKD patients, remain unclear. Our purpose was to identify which of these factors predict incident CVD in CKD. Methods: In this prospective cohort study, we enrolled 738 predialysis outpatients in the two nephrology departments. We employed Cox proportional hazards analyses to elucidate predictors of the endpoint, defined as fatal or non-fatal cardiovascular event requiring hospitalization. Multiple imputation was performed for missing values. Results: Mean estimated glomerular filtration rate (eGFR) was 35 mL/min/1.73 m(2). During a median duration of 4.4 years, 86 patients developed the endpoint, of whom 62 patients achieved it before the initiation of dialysis. Multivariable analyses revealed that high serum intact FGF23 levels predicted the outcome preceding dialysis initiation (hazard ratio (HR) per InFGF23 (SD), 1.64 (1.27-2.30)), while 250, PTH, and bone-specific ALP did not. Adding FGF23 to the conventional model of age, sex, diabetes, prior CVD, pulse pressure, and eGFR, led to a net reclassification improvement of 6.87% (P=0.04). Not censoring the patients at the start of dialysis and continuing follow-up even after dialysis, FGF23 levels did not predict the outcome (HR, 1.16 (0.91-1.48)). Complete case analyses yielded similar results. Conclusions: Intact FGF23 levels in predialysis CKD predicted incident cardiovascular events requiring hospitalization before starting dialysis, but did not predict events during the entire follow-up period, including post dialysis initiation. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:1266 / 1274
页数:9
相关论文
共 50 条
  • [1] Associations of Fibroblast Growth Factor 23 with Parameters of Phosphate Metabolism in Incident Peritoneal Dialysis Patients
    Golembiewska, Edyta
    Safranow, Krzysztof
    Kabat-Koperska, Joanna
    Ciechanowski, Kazimierz
    Bober, Joanna
    Bogacka, Anna
    PERITONEAL DIALYSIS INTERNATIONAL, 2013, 33 (04): : 447 - U143
  • [2] Fibroblast Growth Factor 23 and Incident CKD in Type 2 Diabetes
    Isakova, Tamara
    Craven, Timothy E.
    Lee, Jungwha
    Scialla, Julia J.
    Xie, Huiliang
    Wahl, Patricia
    Marcovina, Santica M.
    Byington, Robert P.
    Wolf, Myles
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 10 (01): : 29 - 38
  • [3] Fibroblast Growth Factor-23 and Cardiovascular Events in CKD
    Scialla, Julia J.
    Xie, Huiliang
    Rahman, Mahboob
    Anderson, Amanda Hyre
    Isakova, Tamara
    Ojo, Akinlolu
    Zhang, Xiaoming
    Nessel, Lisa
    Hamano, Takayuki
    Grunwald, Juan E.
    Raj, Dominic S.
    Yang, Wei
    He, Jiang
    Lash, James P.
    Go, Alan S.
    Kusek, John W.
    Feldman, Harold
    Wolf, Myles
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 25 (02): : 349 - 360
  • [4] The Effects of Storage Time and Repeated Freeze-Thaw Cycles on Intact Fibroblast Growth Factor 23 Levels
    Tang, Rong
    Lu, Yinghui
    Yin, Ru
    Zhu, Ping
    Zhu, Ling
    Zheng, Chunxia
    BIOPRESERVATION AND BIOBANKING, 2021, 19 (01) : 48 - 52
  • [5] C-terminal fragment of fibroblast growth factor 23 improves heart function in murine models of high intact fibroblast growth factor 23
    Hu, Ming Chang
    Reneau, James A.
    Shi, Mingjun
    Takahashi, Masaya
    Chen, Gaozhi
    Mohammadi, Moosa
    Moe, Orson W.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2024, 326 (04) : F584 - F599
  • [6] Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?
    Olauson, Hannes
    Qureshi, Abdul Rashid
    Miyamoto, Tetsu
    Barany, Peter
    Heimburger, Olof
    Lindholm, Bengt
    Stenvinkel, Peter
    Larsson, Tobias E.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (09) : 3033 - 3038
  • [7] Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study
    Garimella, Pranav S.
    Ix, Joachim H.
    Katz, Ronit
    Chonchol, Michel B.
    Kestenbaum, Bryan R.
    de Boer, Ian H.
    Siscovick, David S.
    Shastri, Shani
    Hiramoto, Jade S.
    Shlipak, Michael G.
    Sarnak, Mark J.
    ATHEROSCLEROSIS, 2014, 233 (01) : 91 - 96
  • [8] Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis
    Yamada, Shunsuke
    Tsuruya, Kazuhiko
    Tokumoto, Masanori
    Yoshida, Hisako
    Tatsumoto, Narihito
    Ooboshi, Hiroaki
    Kitazono, Takanari
    THERAPEUTIC APHERESIS AND DIALYSIS, 2017, 21 (01) : 71 - 78
  • [9] Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease
    Scialla, Julia J.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2015, 24 (03) : 260 - 267
  • [10] Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients
    Sarmento-Dias, Margarida
    Santos-Araujo, Carla
    Poinhos, Rui
    Oliveira, Bruno
    Sousa, Maria Joao
    Silva, Liliana Simoes
    Silva, Isabel Soares
    Correia, Flora
    Pestana, Manuel
    CLINICAL NEPHROLOGY, 2016, 85 (03) : 135 - 141